Semax vs Cerebrolysin: Nootropic Peptide Comparison
Semax and Cerebrolysin are both neuropeptides with decades of clinical use in Russia and Europe, yet they differ fundamentally in origin, administration, and mechanism. Semax is a synthetic heptapeptide analog of ACTH(4-10) originally developed at the Institute of Molecular Genetics in Moscow. Cerebrolysin is a porcine brain-derived peptide preparation containing a complex mixture of neurotrophic factors and free amino acids, manufactured by EVER Neuro Pharma in Austria. Both target brain-derived neurotrophic factor (BDNF) pathways and have been studied for cognitive enhancement, neuroprotection, and neurological recovery -- but they occupy very different niches in terms of convenience, evidence base, and intended use cases.
Side-by-Side Comparison
| Category | Semax | Cerebrolysin: Nootropic Peptide Comparison |
|---|---|---|
| Mechanism of action | Synthetic ACTH(4-10) analog that modulates BDNF and NGF expression, enhances dopaminergic and serotonergic neurotransmission, and activates the MAPK/ERK signaling cascade involved in neuronal plasticity. Also demonstrates antioxidant activity by reducing lipid peroxidation in brain tissue. The melanocortin pathway activation provides additional anti-inflammatory effects in the CNS. | A complex mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins. Acts as a multimodal neurotrophic agent -- mimicking the activity of endogenous BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, dendritic arborization, and synaptic repair. Also inhibits calpain-mediated neurodegeneration and reduces amyloid-beta aggregation in preclinical models. |
| Primary research area | Cognitive enhancement, focus and working memory improvement, ADHD-like attention deficits, stroke recovery (approved in Russia for ischemic stroke), and optic nerve atrophy. Most clinical use is for daily nootropic supplementation or post-stroke cognitive rehabilitation. | Stroke recovery, traumatic brain injury (TBI), vascular dementia, and Alzheimer's disease. Positioned as an intensive neurorestorative therapy rather than a daily nootropic. Multiple large-scale clinical trials in post-stroke rehabilitation and moderate Alzheimer's disease. |
| Evidence level | Approved as a prescription drug in Russia and several CIS countries for ischemic stroke and cognitive disorders. Published human studies on stroke recovery, cognitive function in healthy volunteers, and ADHD symptoms. Evidence base is strong within Russian medical literature but limited in Western peer-reviewed journals. No FDA approval or EMA approval. | Over 50 randomized controlled trials published in international peer-reviewed journals. Phase III and IV data for stroke, TBI, and Alzheimer's disease. Cochrane reviews exist for its use in vascular dementia and acute ischemic stroke. Approved in over 40 countries (not including the US). Stronger international clinical trial evidence than Semax. |
| Administration route | Intranasal spray (most common) or subcutaneous injection. The nasal route provides direct access to the CNS via the olfactory pathway and is convenient for daily self-administration. No clinical setting required. | Intramuscular (IM) or intravenous (IV) injection only. Typical protocols involve 10-30 mL IV infusions daily for 10-20 consecutive days. Requires clinical supervision for IV administration. Not available as a nasal spray or oral formulation due to the large molecular weight of the peptide mixture. |
| Typical research dosing | Nasal: 300-600 mcg per day (1-2 sprays per nostril), typically used 5 days on / 2 days off or continuously for 8-12 weeks. Subcutaneous: 200-600 mcg daily. No significant tolerance development reported with standard cycling. | IM: 5-10 mL daily for 10-20 days. IV: 10-30 mL diluted in saline, infused over 15-30 minutes daily for 10-20 days. Treatment courses are repeated every 3-6 months. Not designed for continuous daily use. |
| Key studies/evidence | Aseeva et al. (2006) -- improved cognitive outcomes in post-stroke patients. Kaplan et al. (2012) -- enhanced attention and memory in healthy volunteers. Medvedev et al. (2015) -- Semax effects on BDNF gene expression. Russian Ministry of Health clinical use data for ischemic stroke. Multiple Russian-language clinical trials supporting nootropic effects. | CASTA trial (Heiss et al., 2012) -- Cerebrolysin in acute ischemic stroke, 1,070 patients. Alvarez et al. (2011) -- Cerebrolysin in mild-to-moderate Alzheimer's disease. Chen et al. (2013) -- Cerebrolysin for traumatic brain injury. Cochrane Review (Ziganshina et al., 2020) -- vascular dementia. The international clinical trial database is substantially larger than Semax. |
Can They Be Stacked?
There is no published research on combining Semax and Cerebrolysin. While their mechanisms are not directly antagonistic -- Semax modulates BDNF expression while Cerebrolysin provides exogenous neurotrophic factors -- the combination has not been studied for safety or efficacy. Some clinical practitioners in Russia and Eastern Europe have used both in sequence (Cerebrolysin courses followed by Semax maintenance), but this remains anecdotal.
Verdict
Semax and Cerebrolysin serve different roles in the neuropeptide landscape. Semax is the more practical choice for daily nootropic use -- its nasal administration is convenient, it has a favorable safety profile for long-term use, and it modulates BDNF and dopaminergic pathways in ways that support focus, memory, and cognitive resilience. For individuals seeking a daily cognitive enhancer with neuroprotective properties, Semax is the more accessible option. Cerebrolysin is better positioned as an intensive brain recovery protocol -- its clinical trial data for stroke rehabilitation, TBI, and Alzheimer's disease is substantially stronger and more internationally validated. However, it requires clinical administration (IM or IV), is impractical for daily self-use, and is designed for time-limited treatment courses rather than ongoing supplementation. Neither is FDA-approved. The choice depends on the use case: daily cognitive optimization favors Semax, while intensive neurological recovery favors Cerebrolysin.
Related Comparisons
Selank and Semax are both Russian-developed nootropic peptides approved for clinical use in Russia, making them among the few peptides with actual regulatory approval (outside the US). They are often compared because both target cognitive function, but through very different neurotransmitter pathways.
Dihexa vs SemaxDihexa and Semax are both studied for cognitive enhancement, but they differ dramatically in evidence level and risk profile. Semax is an approved medication in Russia with decades of clinical data, while Dihexa is a potent research compound with limited safety data beyond animal studies.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.